Literature DB >> 11397808

Early intermediates in HIV-1 envelope glycoprotein-mediated fusion triggered by CD4 and co-receptor complexes.

A S Dimitrov1, X Xiao, D S Dimitrov, R Blumenthal.   

Abstract

An early step in the process of HIV-1 entry into target cells is the activation of its envelope glycoprotein (GP120-GP41) to a fusogenic state upon binding to target cell CD4 and cognate co-receptor. Incubation of human immunodeficiency virus (HIV)-1 Env-expressing cells with an excess of CD4 and co-recepeptor-bearing target cells resulted in an influx of an impermeant nucleic acid-staining fluorescent dye into the Env-expressing cells. The dye influx occurred concomitant with cell fusion. No influx of dye into target cells was observed if they were incubated with an excess of Env-expressing cells. The permeabilization of Env-expressing cells was also triggered by CD4.co-receptor complexes attached to Protein G-Sepharose beads in the absence of target cells. The CD4 and co-receptor-induced permeabilization of Env-expressing cells occurred with the same specificity with respect to co-receptor usage as cell fusion. Natural ligands for the co-receptors and C-terminal GP41 peptide inhibitors of HIV-1 fusion blocked this effect. Our results indicate that the process of HIV-1 Env-mediated fusion is initiated by the destabilization of HIV-1 Env-expressing membranes. Further elucidation of these early intermediates may help identify and develop potential inhibitors of HIV-1 entry into cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11397808     DOI: 10.1074/jbc.M103788200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  A peptide pertaining to the loop segment of human immunodeficiency virus gp41 binds and interacts with model biomembranes: implications for the fusion mechanism.

Authors:  Roberto Pascual; Miguel R Moreno; José Villalaín
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

2.  Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virus.

Authors:  Hui Xie; Danny Ng; Sergey N Savinov; Barna Dey; Peter D Kwong; Richard Wyatt; Amos B Smith; Wayne A Hendrickson
Journal:  J Med Chem       Date:  2007-09-06       Impact factor: 7.446

Review 3.  Early events of HIV-1 infection: can signaling be the next therapeutic target?

Authors:  Kate L Jones; Redmond P Smyth; Cândida F Pereira; Paul U Cameron; Sharon R Lewin; Anthony Jaworowski; Johnson Mak
Journal:  J Neuroimmune Pharmacol       Date:  2011-03-05       Impact factor: 4.147

4.  Involvement of clathrin-mediated endocytosis in human immunodeficiency virus type 1 entry.

Authors:  Jessica Daecke; Oliver T Fackler; Matthias T Dittmar; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

Review 5.  Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapy.

Authors:  Himanshu Garg; Mathias Viard; Amy Jacobs; Robert Blumenthal
Journal:  Curr Top Med Chem       Date:  2011-12       Impact factor: 3.295

6.  Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.

Authors:  Maxime Moulard; Sanjay K Phogat; Yuuei Shu; Aran F Labrijn; Xiaodong Xiao; James M Binley; Mei-Yun Zhang; Igor A Sidorov; Christopher C Broder; James Robinson; Paul W H I Parren; Dennis R Burton; Dimiter S Dimitrov
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

7.  Chimeric Cyanovirin-MPER recombinantly engineered proteins cause cell-free virolysis of HIV-1.

Authors:  Mark Contarino; Arangassery R Bastian; Ramalingam Venkat Kalyana Sundaram; Karyn McFadden; Caitlin Duffy; Vamshi Gangupomu; Michelle Baker; Cameron Abrams; Irwin Chaiken
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

8.  A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stability.

Authors:  Chungen Pan; Lifeng Cai; Hong Lu; Lu Lu; Shibo Jiang
Journal:  J Biol Chem       Date:  2011-06-20       Impact factor: 5.157

9.  Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy.

Authors:  J Judy Chang; Fiona Wightman; Angeline Bartholomeusz; Anna Ayres; Stephen J Kent; Joseph Sasadeusz; Sharon R Lewin
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

10.  Structural and functional properties of peptides based on the N-terminus of HIV-1 gp41 and the C-terminus of the amyloid-beta protein.

Authors:  Larry M Gordon; Alex Nisthal; Andy B Lee; Sepehr Eskandari; Piotr Ruchala; Chun-Ling Jung; Alan J Waring; Patrick W Mobley
Journal:  Biochim Biophys Acta       Date:  2008-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.